Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn
- 31 August 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (12) , 1715-1719
- https://doi.org/10.1016/j.ejca.2006.04.008
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.Proceedings of the National Academy of Sciences, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.Proceedings of the National Academy of Sciences, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984